<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00449592</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-06-4196-MKM-CTIL</org_study_id>
    <nct_id>NCT00449592</nct_id>
  </id_info>
  <brief_title>Oral Zinc Therapy for the Prevention of Mucositis</brief_title>
  <official_title>A Ramdomized Double Blined Placebo Controlled Oral Zinc Therapy for the Prevention of Mucositis in Patients Undergoing High Dose Chemotherapy With Stem Cell Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Zinc is an intracellular mineral with important enzymatic cofactor activities for cell&#xD;
      membrane stability, DNA and RNA structure. Zinc deficiency is associated with delayed wound&#xD;
      healing and immune dysfunction. In patietns with hematological malignancies an inverse&#xD;
      correlation was found between disease stage and zinc level. Patients undergoing high dose&#xD;
      chemotherapy for hematologic malignancies are predisposed to develop oral and&#xD;
      gastrointestinal complications, in particular oral mucositis. These patients may have&#xD;
      relative zinc deficiency, therefore oral zinc therapy may be benefical in the prevention of&#xD;
      these complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients candidate for High dose chemotherapy with stem cell support for the diagnosis of&#xD;
      relapsed/resistant Hodgkins or NHL or MM will be screened for enrollment in the study.&#xD;
&#xD;
      Patients will be randomized in a 1:1 ratio to therapy with either zincol 1 Tab TID or placebo&#xD;
      1 Tab TID.&#xD;
&#xD;
      Therapy will start on the morning before commencing chemotherapy and will continue untill the&#xD;
      first of either discharge day or day 21.&#xD;
&#xD;
      Response assesment will include:&#xD;
&#xD;
        1. Mucositis assesment using NCI-CTC and OMAS scores- to be done eod from baseline and&#xD;
           untill day 21/discharge day if before day 21&#xD;
&#xD;
        2. Evaluation of zinc levels in the serum, PBMC and saliva- to be done at baseline, day 6/7&#xD;
           and day 21/discharge day if before day 21.&#xD;
&#xD;
        3. Collection of clinical outcome data regarding infectious complications including-&#xD;
           presence and length of febrile neutropenia,use of antibacterial and antifungal&#xD;
           medications,&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Mucositis grade</measure>
    <time_frame>day -7 to day +21 or discharge day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of maximal mucositis grade</measure>
    <time_frame>day -7 to day +21 or discharge day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall duration of mucositis</measure>
    <time_frame>day -7 to day +21 or discharge day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of severe neutropenia</measure>
    <time_frame>day -7 to day +21 or discharge day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of febrile neutropenia</measure>
    <time_frame>day -7 to day +21 or discharge day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Mucositis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral zinc therapy, intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zinc</intervention_name>
    <description>Oral Zincol 1 Tab TID from day -6/-7 until discharge</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo 1 Tab TID from day -6/-7 until discharge</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing high dose chemotherapy with stem cell support for relapsed or&#xD;
             resistant Hodgkins or NHL (treated with BEAM protocol) or MM (treated with high dose&#xD;
             melphalan).&#xD;
&#xD;
          -  ECOG performance less than or equal to 2&#xD;
&#xD;
          -  Adequate renal and hepatic function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of any other active malignancy other than BCC of the skin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maya Koren-Michowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center</name>
      <address>
        <city>Ramat-Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>March 18, 2007</study_first_submitted>
  <study_first_submitted_qc>March 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2007</study_first_posted>
  <last_update_submitted>October 2, 2008</last_update_submitted>
  <last_update_submitted_qc>October 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Maya Koren-Michovitz</name_title>
    <organization>Sheba Medical Center</organization>
  </responsible_party>
  <keyword>Stem cell transplantation</keyword>
  <keyword>Mucositis</keyword>
  <keyword>Zinc</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

